For the last fifteen months or so, a drumbeat in the background has been sounding regarding the true track record and safety of the inoculations Pfizer, Moderna, AstraZeneca, and Johnson & Johnson developed to help stop the “pandemic” in its tracks.
Since the rollout of the shots, there has been such an increase in the reports of deaths attributed to them as well as adverse events, that one company, Pfizer, had to add staff just to process the documentation. This information was found in the latest tranche of documents ordered released by a judge, and some key points are brought out by The Blaze’s Daniel Horowitz.
Several months ago, the FDA released a Pfizer document on adverse events revealing that there were 42,086 adverse events voluntarily reported to the company, of which 1,223 were fatalities, just as of Feb. 28, 2021. A new unredacted copy of that document, which details nine pages of several thousand known categories of adverse effects, reveals the massive scope of injuries that were being reported to Pfizer and raises questions about what company personnel knew when they knew it, and what they observed in the ensuing months.
In the document, Pfizer reveals that “due to the large numbers of spontaneous adverse event reports,” staff were forced to prioritize “the processing of serious adverse events” and the company had to hire large numbers of staff. “To date, Pfizer has onboarded approximately 600 additional full-time employees (FTEs),” reveals Pfizer on page six of the confidential document. “More are joining each month with an expected total of more than 1,800 additional resources by the end of June 2021.”
Horowitz goes on.
Read this paragraph and ask yourself how many people would have taken the shot had they known this and how the failure to disclose this information is in line with the Nuremberg Code. Also, what is the epilogue of the story? What did Pfizer discover in the ensuing months – to this very day – that it is not disclosing to the public?
When it became apparent to the public earlier in 2021 that myocarditis was a known side effect of the shots, the government and the media immediately claimed the incidence rate was exceedingly low. Numerous “studies” tried to downplay the risks. One paper from Kaiser Permanente in JAMA suggested the rate was just 6.6 per million. Another JAMA study from last June found a 1 in 50,000 rate among the military (which we now know was woefully underreported). Well, thanks to ICAN’s FOIA, we now have the Pfizer informed consent document (p. 5) that shows the company recognized the risk can be as high as 1 in 1,000.
So, all of these stories suggesting that young males were more at risk for myocarditis from the virus than from the shots were bogus, and Pfizer knew it. And again, if this is the degree the company is willing to concede, imagine what the true incidence rate is.
Also, what is the degree of subclinical myocarditis? If we know about this many cases shortly after the injection, who’s to say there isn’t another cohort of people with heart damage that has remained subclinical so far but could come to fruition several months later? Remember, with many fewer vaccines administered in 2022, the rate of myocarditis reports to VAERS is averaging 245% higher than last year.
And this is just what is being reported. What is not being reported is a scarier prospect. It would explain why so many world-class athletes are having chest pains, though.
Oh, but that’s not all of the incredulity Horowitz writes:
Pfizer never studied the efficacy of the shots exclusively among those with prior infection. Bizarrely, a new document reveals researchers studied them together; however, they break down the results in a way that reveals no need for the shots among those with prior infection. Here is the money quote from p. 12 of Pfizer’s “request for priority review” in May 2021:
“Among participants without evidence of SARS-CoV-2 infection before and during the vaccination regimen (evaluable efficacy population), the estimated VE against FDA-defined severe COVID-19 (protocol definition) occurring at least 7 days after Dose 2 was 95.3% (2-sided 95% CI: 71.0%, 99.9%), with 1 and 21 cases in the BNT162b2 and placebo groups, respectively. Similarly, the estimated VE was also 95.3% (2-sided 95% CI: 70.9%, 99.9%) among participants with or without evidence of SARS-CoV-2 infection, also with 1 and 21 cases in the BNT162b2 and placebo groups, respectively.”
Pfizer claims efficacy against severe illness among those who took the shot vs. the placebo group among those without prior infection. Researchers report one case in the trial group and 21 in the placebo group. Then they mix together results of those with and without prior infection, and yet the numbers remain the same at 1 and 21 respectively! That means that among those with prior infection, there were zero cases of serious reinfection in both the trial and placebo groups. They might call that 100% effective, but we can also call that 0% effective. Thus, they knew people didn’t need the shot if they already had a prior infection, but they promoted it anyway and still got approval.
So, the people who got the bug didn’t need the shots and a whole lot of them got them anyway.
And the FDA did not put a stop to all of this.
Food for thought.
— Jean Rees (@JeanRees10) March 27, 2022